Some of the most important cells in wound healing are keratinocytes, responsible for reepithelialization, and endothelial cells, which manage angiogenesis: to close the disrupted epidermal layer, keratinocytes migrate from the wound edge across the wound bed.^[@R1]^ On large-scale burn wounds, coverage with keratinocytes is often achieved by split skin grafts, keratinocyte sheets, or application of keratinocytes with scaffold-like fibrin sealant spray.^[@R2]^ Endothelial cells invade the granulation tissue, form new vessels, and thereby supply the newly formed extracellular matrix with oxygen and nutrients.

Botulinum (neuro)toxin A(BoNT) is a neurotoxin produced by the bacterium *Clostridium botulinum*, which induces chemodenervation of muscles by preventing the release of neurotransmitters such as acetylcholine and noradrenaline.^[@R3]^ It was primarily found in adulterated meat products by causing botulism. Nowadays, BoNT is commonly used in medical applications to treat chronic myofascial pain,^[@R4]^ headache,^[@R5]^ urinary incontinence,^[@R6]^ and hyperhidrosis^[@R7]^ or in cosmetic applications^[@R8],[@R9]^ among others.

Recently, the effect of botulinum toxin on mature adipocytes, and also adipose-derived stem cells, and fibroblasts was evaluated in vitro.^[@R10]^ Botulinum toxin was shown to have no negative effect on adipose-derived stem cells, mature adipocytes, or fibroblasts. BoNT was also used as an adjuvant in autologous fat transfer in vivo where a higher fat graft survival could be achieved.^[@R11]^ Also, good results in wound healing were reported as BoNT had an effect on the tension in the wound edges with deleterious effects.^[@R12]^ A variety of predominantly clinical studies examined the impact of BoNT on wound healing, and most of them concluded that an early injection of botulinum toxin type A seems to enhance healing of facial wounds.^[@R13]--[@R15]^

Therefore, we wanted to evaluate the effect of botulinum toxin type A (BoNT) on wound healing on a cellular level. We tested the proliferation and migration of human keratinocytes and endothelial cells and the angiogenic behavior of endothelial cells in vitro.

MATERIALS AND METHODS
=====================

Cultivation of Human Umbilical Vein Endothelial Cells and Keratinocytes
-----------------------------------------------------------------------

Human umbilical vein endothelial cells (HUVECs) were kindly provided by the Cardiac Surgery Research Laboratories (Dr. Barbara Messner, Medical University of Vienna, Vienna, Austria). Umbilical cords were kindly donated by the Department of Gynecology, Medical University of Vienna, and isolation of cells is approved by the local ethics committee (EK number: 1280/2015). All donors gave written informed consent prior inclusion. Briefly, the umbilical cord vein was washed using sterile phosphate-buffered saline (PBS) to remove blood residues and afterward perfused with collagenase (type IV, 1 mg/mL) for 20 minutes at room temperature. After rinsing out the collagenase--endothelial cell suspension with sterile prewarmed RPMI medium (Lonza; Basel, Switzerland), HUVECs were collected by centrifugation. Cells were cultured on gelatin-coated (0.2% gelatin) cell culture flasks and using specialized endothelial cell culture medium (endothelial growth medium 2 \[EGM-2\], Lonza). Purity of cells reached at least 95% (checked by staining with anti-CD31 antibody and flow cytometry analyses) and was used for experiments within passages 1 and 5.

Keratinocytes (Evercyte GmbH; Vienna, Austria) were cultured in DermaLife K Complete Medium (CellSystems; Troisdorf, Germany). Cells between passages 3 and 8 were used for experiments.

Treatment of Cells with BoNT
----------------------------

Cells were seeded into multiwell plates, depending on the cell assay. The medium was removed, and cells were incubated with 1-, 10-, and 20-IU/mL onabotulinumtoxin A (Botox, Allergan Inc.; Irvine, Calif.), respectively. To obtain different concentrations, a stock solution (200 IU/mL) was diluted with the corresponding proliferation medium. As control, cells were incubated with medium only.

Proliferation
-------------

Keratinocytes and HUVECs were seeded in 96-well plates (8 × 10^4^ cells per well). After 24 hours of cultivation, medium was changed to BoNT-containing proliferation medium. As a control, normal proliferation medium without BoNT was added to the cells. The cell number on days 1, 2, and 3 was evaluated using a CellTiter96 nonradioactive proliferation assay (MTT-Assay, Promega; Madison, Wis.) according to the manufacturer's protocol, and absorbance was measured on a Wallac 1420 VICTOR2 plate reader (PerkinElmer; Waltham, Mass.).

Migration: In Vitro Scratch Assay
---------------------------------

Cells were cultured in 12-well plates until they reached 100% confluence and were then scratched with a 1-mL plastic micropipette tip. Cells were rinsed with PBS to remove detached cells and incubated with BoNT-containing proliferation medium. Control cells were cultivated in proliferation medium without BoNT. Cells were analyzed using an inverted Nikon Eclipse Ti-E microscope (Nikon; Tokyo, Japan). Wound area was measured with the NIS-Elements AR 3.0 program (Nikon; Tokyo, Japan) directly after scratching and after 24, 48, 72, and 118 hours (until wound closure).

Angiogenesis: In Vitro Tube-Forming Assay
-----------------------------------------

Matrigel (basement membrane matrix, growth factor reduced, BD Biosciences; Bedford, Mass.) was filled into µ-slide angiogenesis chambers (ibidi; Martinsried, Germany) and was polymerized for 30 minutes at 37°C. HUVECs were seeded onto the Matrigel and were incubated with different concentrations of BoNT mixed with the EGM-2 (Lonza; Basel, Switzerland) containing vascular endothelial growth factor (VEGF). After 6 hours of incubation, the cells were photographed with an inverted Nikon Eclipse Ti-E microscope (Nikon; Tokyo, Japan), and the number of tubes, the total tube length, the number of loops and branching points, and the covered area in percent were calculated by Wimasis (Wimasis GmbH; Munich, Germany).

Angiogenesis: Spheroid-based In Vitro Sprouting Assay
-----------------------------------------------------

Cell spheroids were generated as described by Korff et al.^[@R16]^ For the sprouting assay, spheroids were embedded into collagen gels as described in Testori et al.^[@R17]^ In short, cells were grown overnight in spheroids in hanging drops containing 0.25% methylcellulose. Approximately 450 cells formed a spheroid, which was mixed with rat collagen and 80% of Methocel/20% of fetal calf serum. The hydrogels with the spheroids were incubated with different concentrations of BoNT. Endothelial basal medium 2 (Lonza; Basel, Switzerland) without supplements was used as negative control, and medium containing 30-ng/mL VEGF was used as positive control. After 20 hours of incubation, the cumulative sprout length for each spheroid was calculated with the cellSens Entry 1.8 program (Olympus Tokyo, Japan).

Real-time Polymerase Chain Reaction Analysis
--------------------------------------------

HUVECs were seeded into 6-well plates and incubated with different concentrations of BoNT mixed with the EGM-2. Cells with proliferation medium without BoNT were used as control. After 6 hours of incubation, total RNA was prepared by homogenizing cells in lysis buffer containing 0.1% 2-mercaptoethanol followed by RNA extraction according to a standard protocol (RNeasy Mini Kit, Qiagen GmbH; Hilden, Germany). RNA was transcribed into cDNA by QuantiTect Reverse Transcription Kit (Qiagen). Quantitative real-time polymerase chain reaction (qPCR) was performed using the KAPA SYBR FAST qPCR Kit (peqlab, VWR; Darmstadt, Germany) with primers for VEGF-A, angiopoietin-2 (ANGPT2), and matrix metalloproteinase 9 (MMP9) normalized to glyceraldehyde 3-phosphate dehydrogenase expression as endogenous control (all Microsynth; Balgach, Switzerland). Expression of specific mRNA in each sample was quantitated in duplicates on an ABI PRISM 7000 Cycler (Applied Biosystems, Foster City, Calif.).

Statistic
---------

Statistical analysis was performed with the GraphPad Prism statistic software (GraphPad Software, Inc.; La Jolla, Calif.). Data are presented as mean ± SEM of at least 3 independent experiments. Statistical comparisons were based on paired *t* test and 1-way analysis of variance followed by Dunnett's multiple comparison test with *P* \< 0.05 considered as significant.

RESULTS
=======

High Concentrations of BoNT Have a Negative Effect on Keratinocytes' Proliferation and Migration
------------------------------------------------------------------------------------------------

Proliferation of keratinocytes and HUVECs was observed by measuring the cell number after 24, 48, and 72 hours of incubation with BoNT. Proliferation of keratinocytes was decelerated when incubated with 20 IU/mL BoNT. This effect was significant after 24 and 48 hours but was compensated after 72 hours of cell proliferation (Fig. [1](#F1){ref-type="fig"}A). In contrast, endothelial cells showed no significant differences in cell proliferation over 3 days (Fig. [1](#F1){ref-type="fig"}B).

![Proliferation of keratinocytes (A) and HUVEC (B) exposed to BoNT after 24, 48, and 72 h. Cell numbers were normalized and related to control (24 h = 100%); n = 3, \**P* \< 0.05 and \*\**P* \< 0.01.](gox-4-0e837-g001){#F1}

In an in vitro scratch assay, high BoNT concentrations of 20 IU/mL had a negative effect on keratinocytes' migration as the scratch is closed significantly slower compared with the medium control (Fig. [2](#F2){ref-type="fig"}A). No significant effect could be observed with HUVECs (Fig. [2](#F2){ref-type="fig"}B).

![In vitro wound healing assay of keratinocytes (A and C--E) and HUVECs (B and F--H) exposed to BoNT for 0 h (C and F), 24 h (G), 48 h (D and H), and 72 h (E). Data were normalized and related to baseline (0 h = 100%); n = 3, \**P* \< 0.05; magnification, 40×.](gox-4-0e837-g002){#F2}

High Concentrations of BoNT Have a Negative Effect on Neoangiogenesis
---------------------------------------------------------------------

HUVECs were seeded in a basal membrane and incubated with different concentrations of BoNT (Fig. [3](#F3){ref-type="fig"}). Compared with medium control, HUVEC built significant fewer tubes when incubated with 20-IU/mL BoNT. Also the total tube length was less with the highest BoNT concentration tested (Fig. [4](#F4){ref-type="fig"}A, B). Significant differences could also be shown in the quality of the tubes: both the number of built vessel loops and the branching points between the vessels were fewer with 20-IU/mL BoNT compared with the control (Fig. [4](#F4){ref-type="fig"}C, D). Concerning the cell-covered area, no differences between the samples could be observed.

![Tube-forming assay of HUVEC on Matrigel incubated with growth medium (A), BoNT 1 IU/mL (B), 10 IU/mL (C), and 20 IU/mL (D); magnification, 40×.](gox-4-0e837-g003){#F3}

![Evaluation of tube-forming assay. Number of tubes (A), total tube length (B), number of loops (C), and branching points (D), and also the cell-covered area (E) were measured; n = 4, \**P* \< 0.05.](gox-4-0e837-g004){#F4}

In sprouting assay experiments, cell spheroids were encapsulated into a hydrogel and had to migrate and invade into the surrounding to build vessel-like structures. Compared with the negative control, low BoNT concentrations of 1 and 10 IU/mL enhanced sprouting of endothelial cells, and more vessels were formed. Spheroids treated with 20-IU/mL BoNT did not build more sprouts than the negative control (Fig. [5](#F5){ref-type="fig"}).

![In vitro angiogenesis assay/sprouting assay: spheroids of HUVEC were incubated with basal medium (control), BoNT 1, 10, 20 IU/mL, and 30 ng/mL VEGF for 20 h. A minimum of 30 randomly selected spheroids were used for quantification of the cumulative sprout length. \*\**P* \< 0.01 and \*\*\**P* \< 0.001.](gox-4-0e837-g005){#F5}

Real-time PCR analysis showed significantly lower expressions of VEGF-A, ANGPT2, and MMP9 in higher BoNT levels (Fig. [6](#F6){ref-type="fig"}).

![Expression of genes relevant for neoangiogenesis: HUVECs were incubated with basal medium (control), BoNT 1, 10, and 20 IU/mL for 6 h. Expression of VEGF-A (A), ANGPT2 (B), and MMP9 (C) is shown relative to control (100%); n = 3, \**P* \< 0.05 and \*\**P* \< 0.01.](gox-4-0e837-g006){#F6}

DISCUSSION
==========

A variety of studies show that botulinum toxin type A injections induce temporary muscular paralysis and relieve the tension on wound edges. This relief of tension may help prevent the widening, hypertrophy, and hyperpigmentation of facial scars.^[@R12],[@R13]^ Only few studies have been conducted that investigate the biological effects of BoNT in terms of wound healing beyond the effect of immobilization. However, it has been shown that BoNT inhibits fibroblast proliferation and in addition promotes apoptosis of fibroblasts derived from hypertrophic scars.^[@R18]^ BoNT has also been reported to reduce the expression of transforming growth factor beta-1.^[@R19]^ Therefore, it has even been suggested that BoNT might be used to decrease fibrosis. Clinical results suggest that it would benefit in early stages of scar formation when fibroblasts have stronger proliferative and apoptotic activity.

In a preceding study, we observed the effect of BoNT regarding fat transplantation. In that course, we still tested BoNT on normal human fibroblasts and could show that there is no negative influence on these cells.^[@R10]^ Nevertheless, a comparison between normal human fibroblasts and scar-derived fibroblasts would be interesting.

In our present study, we focused on the behavior of keratinocytes and endothelial cells under the influence of BoNT in different concentrations to observe its impact on wound healing. An in vitro scratch assay imitates wounding in vivo by damaging a confluent cell layer and destruct cell--cell contact. Therefore, cell migration is triggered. We were able to show that in the highest concentration of 20 IU/mL, BoNT had a diminishing effect on keratinocyte migration and proliferation. Lower concentrations of BoNT did not show such an effect. Therefore, a low BoNT concentration is suggested to be used for fast reepithelialization.

In several in vivo studies, it was shown that BoNT increases blood supply, which accelerates the process of healing^[@R20]^ and prevents the collapse of the peripheral vessels in the cutaneous flap. Additionally, increased diameters of arterioles and venules were observed histologically.^[@R21]^

In our study, we observed the effect of BoNT on a cellular basis. We used tube-forming assays and spheroid-sprouting assays to evaluate the impact of different concentrations of BoNT on angiogenesis. We were able to detect reduced vessel formation with endothelial cells in vitro in the tube-forming assay with high BoNT concentrations of 20 IU/mL. The tube formation assay is one of the most widely used in vitro assays to model the early stages of angiogenesis.^[@R22]^ Endothelial cells were plated on a hydrogel of basement matrix, which supports the cells to form capillary-like structures. Tube formation is typically quantified by measuring the number, length, complexity, or area of these structures. The assay can be used to identify inhibitors or stimulators of angiogenesis. This assay involves endothelial cell adhesion, migration, protease activity, and tubule formation.^[@R23]^ In gene expression level, endothelial cells had a significantly reduced VEGF-A and ANGPT2 expression after 6 hours when incubated with high BoNT concentrations. This indicates a reduced potency for neoangiogenesis. Furthermore, a sprouting assay can identify proangiogenic and antiangiogenic effects of test substances. The assay simulates the entire angiogenesis process in vitro in 3 dimensions: proliferation, invasion, migration, and proteolytic activity of endothelial cells. In contrast to the tube formation assay, also three-dimensional networks can be observed. The number and length of the sprouts correspond with the pro- or antiangiogenicity of the test substance. Again, in our experimental setting, we were able to observe an inhibition of angiogenesis when spheroids were treated with high BoNT concentrations of 20 IU/mL. This corresponds with a significant downregulation of MMP9 in endothelial cells, which were incubated with 20-IU/mL BoNT for 6 hours (Fig. [6](#F6){ref-type="fig"}). Low concentrations of 1 and 10 IU/mL enhanced sprouting of endothelial cells with more vessels being formed compared with the negative control. In contrast, no influence of BoNT on proliferation or migration of endothelial cells could be observed.

As already discussed in a previous study,^[@R10]^ a wide range of concentrations of BoNT is used in the clinical settings. In the literature, concentrations between 1 and 10 IU/mL were used^[@R11],[@R24]--[@R26]^; according to the package inserts, a dose of 5 IU per injection for overactive bladder, 1.25 to 2.5 units per injection for blepharospasm or strabismus (Botox),^[@R27]^ and 4 IU per intramuscular injection (Botox Cosmetic, Allergan Inc., Irvine, Calif.)^[@R28]^ are recommended. Furthermore, medical use generally involves significantly higher doses than cosmetic treatment.^[@R29]^ Therefore, we tested 1 and 10 units per mL, and also 20 IU as a high dose of BoNT.

Chang et al^[@R30]^ revealed that several clinical studies showed that BoNT can improve facial scars,^[@R14],[@R31],[@R32]^ but so far no proven explanation for the benefit of BoNT on a cellular level could be provided.

In this study, we showed an important effect of BoNT on cells important for wound healing: High doses of BoNT (20 IU/mL) had a diminishing effect on wound closure by decelerating proliferation and migration of keratinocytes, thereby inhibiting reepithelialization. Additionally, those high concentrations diminished angiogenesis by showing a negative effect on vessel formation by endothelial cells.
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